Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.
Belgium
Biomarkers, Tumor
/ genetics
Early Detection of Cancer
Gene Fusion
Genetic Predisposition to Disease
Humans
Immunohistochemistry
Laboratory Proficiency Testing
Neoplasms
/ genetics
Observer Variation
Phenotype
Predictive Value of Tests
Receptors, Nerve Growth Factor
/ genetics
Reproducibility of Results
Cancer screening
Immunohistochemistry
NTRK fusions
Ring trial
TRK inhibitor
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
11
05
2020
accepted:
01
09
2020
revised:
03
07
2020
pubmed:
12
9
2020
medline:
30
3
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2 fusion positive and 2 samples with wild-type endogenous TRK expression. Each participating laboratory stained the slides using their routine pan-TRK IHC and reported their results. In addition, they were asked to return one TRK-stained slide from each case. The coordinating lab evaluated these slides, compared them with the reference method and scored them. Two clones were used during the ring trial: A7H6R (Cell Signaling) and EPR17341 (Abcam/Ventana). Seven protocols achieved a sufficient performance mark, and three labs were advised to further optimise the protocol. Interpretation of pan-TRK IHC proved to be challenging in cases with physiological TRK expression. In addition, depending on the NTRK fusion partner, the staining can vary strongly in both intensity and staining pattern. Labs using the Ventana ready-to-use system based on the EPR17341 clone and using the recommended protocol settings scored best. However, given some small optimisation, all labs scored well on the technical staining and the succeeding evaluation.
Identifiants
pubmed: 32915263
doi: 10.1007/s00428-020-02921-6
pii: 10.1007/s00428-020-02921-6
pmc: PMC7969564
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Nerve Growth Factor
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-291Références
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Nat Genet. 1998 Feb;18(2):184-7
pubmed: 9462753
Mol Clin Oncol. 2014 Sep;2(5):725-730
pubmed: 25054037
Cancer Discov. 2015 Oct;5(10):1049-57
pubmed: 26216294
Am J Surg Pathol. 2017 Nov;41(11):1547-1551
pubmed: 28719467
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):513-523
pubmed: 27028240
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979374
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Virchows Arch. 2020 Feb;476(2):295-305
pubmed: 31423558
Mod Pathol. 2020 Jan;33(1):38-46
pubmed: 31375766
Arch Pathol Lab Med. 2011 Dec;135(12):1606-10
pubmed: 22129193
JCO Precis Oncol. 2018;2018:
pubmed: 30215037
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
Cancer Res. 2019 Jul 1;79(13):3163-3168
pubmed: 31196931
J Clin Invest. 2013 Nov;123(11):4935-44
pubmed: 24135138
J Neurosci. 1995 Feb;15(2):1567-76
pubmed: 7869118
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):194-196
pubmed: 30920961
JCO Precis Oncol. 2018;2018:
pubmed: 30637364
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22
pubmed: 31738428
Mod Pathol. 2020 May;33(5):924-932
pubmed: 31792356
Biometrics. 1977 Jun;33(2):363-74
pubmed: 884196
Onco Targets Ther. 2019 Apr 30;12:3171-3179
pubmed: 31118670
J Natl Cancer Inst. 2017 Dec 1;109(12):
pubmed: 29370427
Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):719-724
pubmed: 32187023
Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545-64
pubmed: 16939974
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii5-viii15
pubmed: 31738427